Platelet microparticles are a normal constituent of circulating blood. Several studies have demonstrated positive correlations between thrombotic states and platelet microparticle levels. Yet little is known about the processes by which platelet microparticles are generated in vivo. We now characterize microparticles derived directly from megakaryocytes. Video microscopy of live mouse megakaryocytes demonstrated that microparticles form as submicron beads along the lengths of slender, unbranched micropodia. These microparticles are CD41 + , CD42b + , and express surface phosphatidylserine. Megakaryocyte microparticle generation is resistant to inhibition of microtubule assembly, which is critical to platelet formation, and augmented by inhibition of actin polymerization. To determine whether circulating microparticles are derived primarily from activated platelets or megakaryocytes, we identified markers that distinguish between these two populations. CD62P and LAMP-1 were found only on mouse microparticles from activated platelets. In contrast, full-length filamin A was found in megakaryocyte-derived microparticles, but not microparticles from activated platelets. Circulating microparticles isolated from mice were CD62P -, LAMP-1 -and expressed full-length filamin A indicating a megakaryocytic origin. Similarly, circulating microparticles isolated from healthy volunteers were CD62P -and expressed full-length filamin A. Cultured human megakaryocytes elaborated microparticles that were CD41 + , CD42b + , and express surface phosphatidylserine. These results indicate that direct production by megakaryocytes represents a physiologic means to generate circulating platelet microparticles.
Abstract
Platelet microparticles are a normal constituent of circulating blood. Several studies have demonstrated positive correlations between thrombotic states and platelet microparticle levels. Yet little is known about the processes by which platelet microparticles are generated in vivo. We now characterize microparticles derived directly from megakaryocytes. Video microscopy of live mouse megakaryocytes demonstrated that microparticles form as submicron beads along the lengths of slender, unbranched micropodia. These microparticles are CD41 + , CD42b + , and express surface phosphatidylserine. Megakaryocyte microparticle generation is resistant to inhibition of microtubule assembly, which is critical to platelet formation, and augmented by inhibition of actin polymerization. To determine whether circulating microparticles are derived primarily from activated platelets or megakaryocytes, we identified markers that distinguish between these two populations. CD62P and LAMP-1 were found only on mouse microparticles from activated platelets. In contrast, full-length filamin A was found in megakaryocyte-derived microparticles, but not microparticles from activated platelets. Circulating microparticles isolated from mice were CD62P -, LAMP-1
Introduction
Many cells, including platelets, endothelial cells, leukocytes, and erythrocytes, shed fragments of their plasma membranes into the circulation. There is increasing evidence that these submicron fragments, termed microparticles, have important physiological roles. 1 Platelet microparticles are the most abundant microparticles in the bloodstream constituting approximately 70% to 90% of circulating microparticles. [2] [3] [4] Evidence that platelet microparticles participate in thrombus formation is derived from several sources.
Castaman's defect, an isolated deficiency in the ability to generate platelet microparticles, is associated with a bleeding tendency. 5, 6 Platelets from patients with Scott's syndrome also demonstrate an impaired ability to generate platelet microparticles and display a bleeding diathesis. In contrast, elevated platelet microparticle levels are associated with several disease states including heparin-induced thrombocytopenia, 7 arterial thrombosis, 8, 9 idiopathic thrombocytopenic purpura, thrombotic thrombocytopenia, 10 sickle cell anemia disease, 11 and uremia. 12 Platelet microparticles have also been implicated in the pathogenesis of atherosclerosis as well as the regulation of angiogenesis. 13, 14 Despite their apparent participation in important pathological processes, fundamental aspects of platelet microparticle physiology remain unexplored.
The origin of circulating platelet microparticles is among the most poorly understood aspects of microparticle physiology. Platelet microparticles are routinely formed in vitro following exposure to pharmacological concentrations of platelet agonists such as the combination of thrombin and collagen. This observation has contributed to the widely held assumption that circulating platelet microparticles are derived from activated platelets. These microparticles are typically characterized on the basis of several factors, including their small
For personal use only. on October 3, 2017 . by guest www.bloodjournal.org From size (< 1 μm), α IIb β 3 or GPIb expression, and exposure of phosphatidylserine (PS) on their outer membrane as indicated by annexin V binding. Although the mechanisms are not clearly elucidated at the molecular level, platelet microparticle formation appears to involve elevation of cytosolic calcium [15] [16] [17] and loss of membrane-cytoskeletal adhesion. [18] [19] [20] Calpaindependent cleavage of proteins of the membrane skeleton underlying the plasma membrane contributes to loss of membrane-cytoskeletal adhesion and correlates with vesiculation of platelet membranes. 18, [21] [22] [23] Membrane composition, particularly PIP 2 levels, also influences membrane-cytoskeletal adhesion 19, 24 and platelet microparticle formation. 20 Other processes such as activation-induced protein tyrosine dephosphorylation, 25 protein phosphorylation, 26 and calmodulin activation 26 have been implicated in the generation of microparticles from activated platelets.
Yet platelet microparticles circulate in healthy individuals and have been proposed to function in normal hemostasis. 4 Microparticles expressing platelet specific markers are present in the plasma of healthy individuals at concentrations approximately 3%
of that of circulating platelet concentrations. 27 While platelet activation in disease states can result in elevated microparticle levels in vivo, there is no proof that platelet microparticles that circulate in healthy individuals are derived from activated platelets. Thus, a mechanism other than activation of mature platelets may be responsible for the population of platelet microparticles that circulates in healthy individuals. 
Materials and Methods
Materials. All chemicals and reagents were of molecular biology grade. Latrunculin A was obtained from Molecular Probes (Eugene, OR). Nocodazole was purchased from Sigma (St.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Louis, MO). The final concentration of DMSO in cell culture medium never exceeded 0.001% (v/v), and this concentration of DMSO had no effect on proplatelet formation, actin polymer levels, or megakaryocyte-derived microparticle formation. Thrombin was from Sigma (St. Louis, MO) and collagen was from Chrono-log (Havertown, PA). Annexin V-FITC, anti-human CD62P-PE, anti-mouse CD62P-FITC, anti-mouse LAMP-1-FITC, antihuman CD41-PE, anti-mouse CD41-PE, anti-human CD42b-FITC, and anti-mouse CD42b-PE antibodies were from BD Pharmingen (San Jose, CA). Anti-mouse GPVI-FITC and antimouse integrin α 2 -FITC was purchased from Emfret (Wurzburg, Germany). Rabbit polyclonal anti-mouse filamin A was generated using the ABD domain of filamin A.
Mouse megakaryocyte cultures. Livers were recovered from mouse fetuses and single cell suspensions were generated using methods described previously.
34 Cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco) supplemented with 10% fetal bovine serum, 2 mmol/L Glutamax, 50 U/mL penicillin, 50 mg/ml streptomycin, and 100 ng/ml recombinant thrombopoietin (DMEM complete). Cells were placed on a 1.5-3% albumin (fatty-acid free) step gradient and sedimented to obtain enriched populations of megakaryocytes. Day 3 megakaryocytes were evaluated. IACUC approval was obtained for the isolation and purification of mouse megakaryocytes from fetal mouse liver and for the drawing of blood for in vitro studies.
Megakaryocyte-bone marrow endothelial cell coculture. Megakaryocytes were cultured using methods adapted from those previously described. 35 µg/ml insulin, 40 µg/ml low-density lipoproteins, and 50 ng/mL recombinant thrombopoietin. 36, 37 Cells were maintained at <1 X 10 5 /ml with bi-weekly media changes.
On day 14 of culture, cells were harvested, counted, and prepared for electron microscopy.
Greater than 90% of these cells were CD41 + by flow cytometry. The supernatant was collected for microparticle isolation and frozen at -80 o C. Supernatants were subsequently thawed and microparticles analyzed by flow cytometry.
DIC microscopy of microparticle formation. Megakaryocytes were cultured in DMEM within video chambers and were kept at 37°C and a 5% CO 2 atmosphere using methods described previously. 31 Preparations were maintained at 37°C with constant 5% carbon dioxide gas infusion using an Incubator XL-3 incubation chamber (Carl Zeiss, Germany), and examined on a Zeiss Axiovert 200 microscope equipped with a 100x objective (NA 1. Microparticle preparations. For analysis of murine platelet microparticles, blood was drawn from wild-type C57BL/6J mice by vena caval puncture and anticoagulated with acid citrate dextrose (ACD). Platelet-rich plasma (PRP) was subsequently isolated from blood by centrifugation at 400 g for 5 mins. Platelets were removed from PRP following addition of 1 μM PGE 1 (Calbiochem, San Diego) by serial centrifugation at 1000 g for 10 mins.
Microparticles within platelet-poor plasma were used for subsequent studies. To prepare microparticles from activated platelets, washed mouse platelets were incubated with 1 U/ml thrombin and 50 μg/ml collagen at 37 o C for 45 min. Following activation, platelets were removed by serial centrifugation at 1000 g for 10 min. Microparticles were isolated from megakaryocyte cultures by centrifugation at 200 g for 20 min to remove megakaryocytes followed by centrifugation at 1000 g for 10 min to remove any platelets or proplatelets.
Freshly prepared microparticles were analyzed by flow cytometry.
Evaluation of resting platelets. Platelet-rich plasma was prepared by centrifugation and incubated with 25 μg/ml lepirudin, a direct thrombin inhibitor. Samples were incubated endover-end in an orbital shaker. Samples were analyzed at the indicated times for P-selectin surface expression by flow cytometry, cleavage of filamin A by immunoblot analysis, and platelet microparticle production by flow cytometry. Statistical Analysis. For measurement of microparticle formation by flow cytometry, mean + standard deviations were calculated from 3-6 independent studies, as indicated in the figure legends. Statistical significance of differences between groups was determined using a twotailed Student T-test. Significance was set at p < 0.05.
Results

Visualization of microparticle formation from mouse megakaryocytes
Preliminary observations made while studying platelet formation in mouse megakaryocytes indicated that, in addition to generating proplatelets, megakaryocytes form markedly smaller particles that are distinct from platelets. To evaluate the hypothesis that megakaryocytes produce microparticles, megakaryocytes isolated from mouse fetal liver were cultured in suspension as previously described.
31,34 High-resolution differentialinterference contrast (DIC) microscopy of day 3 megakaryocytes revealed striking features that have not been previously recognized, and emphasizes the dynamic nature of microparticle generation. These studies showed that microparticles formed as submicron beads along the length of slender micropodia ( Fig. 1A ; Supplemental Movies 1, 2, and 3).
These beads were substantially smaller than platelet-sized bulges that form proplatelets. The beads formed submicron particles that were released from the megakaryocytes into the culture medium. The degree of shedding of microparticles was indicated by the numerous vesicles observed surrounding the cell.
Although DIC microscopy provided sufficient resolution to visualize microparticles forming as beads along slender micropodia, it was difficult to assess using this technique whether microparticles also formed along the surface of the megakaryocyte plasma membrane. We used the Richardson Technology Microscopy, an optical imaging system capable of particle resolution below 150 nm, to reveal the spatial and temporal dynamics of microparticle formation at the surface of megakaryocytes in culture. These studies showed that day 3 megakaryocytes formed blebs along their surface ( Figure 1B ; Supplemental Movie 4) and emphasized the highly dynamic nature of this process. The blebs observed in these cells involved the entire surface of the cell. Peripheral organelle exclusion from blebs and microparticles was apparent. Microparticles formed without the addition of any platelet agonists to the culture medium. Consistent with our video microscopy analysis, electron microscopy of cultured mouse megakaryocytes revealed particles of 0.2-0.5 μm emanating from the mouse megakaryocyte surface (Fig. 1C,D) . These structures did not appear to contain any organelles and lacked any recognizable cytoskeletal structures such as microtubules or actin filaments. Together, these microscopy studies demonstrate generation of submicron particles by megakaryocytes.
The fact that the submicron particles are released from mouse megakaryocytes enabled us to isolate and characterize these particles from megakaryocyte suspensions.
Platelet microparticles are typically identified by their small size (<1 μm), expression of platelet markers such as CD41 or CD42b, and expression of PS on their extracellular surface.
Analysis of day 3 megakaryocyte suspensions by flow cytometry demonstrated 3 populations that could be distinguished on the basis of their forward and side scatter characteristics.
First, we identified a cell population with forward and side scatter characteristics identical to those of mouse platelets ( Fig. 2A, green) . Populations of particles with forward and side scatter characteristics consistent with microparticles ( Fig. 2A , pink) and megakaryocytes ( Fig. 2A, aqua) were also observed. Following removal of megakaryocytes and platelets by low speed centrifugation, the microparticle population was isolated by ultracentrifugation.
Double staining of the microparticle population with FITC-labeled annexin V and a phycoerythrin-labeled antibody directed at CD41 demonstrated that the majority of these particles expressed surface PS and CD41 (Fig. 2B) . Analysis for additional platelet surface proteins demonstrated that binding of antibodies directed again CD42b was increased 6.3-fold for CD42b (P = 0.0002), 3.1-fold for GPVI (P = 0.003), and 3.2-fold for α 2 integrin (P = 0.005) compared with isotype-matched control antibodies (Fig. 2C ). The population of CD41 + microparticles increased as a function of time in culture (Fig. 2D) generation under these two conditions (P = 0.2). Similarly, we did not observe differences in microparticle formation when megakaryocytes were incubated in the presence versus the absence of TPO, with 1% versus 10% fetal calf serum, or in the presence versus the absence of VEGF165, insulin-like growth factor, SDF-1, and FGF-4 (data not shown).
These data do not rule out an effect of bone marrow endothelial cells or specific cytokines on megakaryocyte microparticle production, but suggest that these factors are not specifically required for stimulating megakaryocyte microparticle formation. We used nocodazole to evaluate the role of microtubules in microparticle formation. At concentrations > 1 μM, nocodazole blocks proplatelet formation. 30-32 However, incubation of cultured megakaryocytes with 1 μM or 5 μM nocodazole failed to inhibit generation of microparticles from megakaryocyte suspensions (Fig. 4) . In contrast, proplatelet formation and platelet production were markedly inhibited in these cultures as observed previously. (data not shown). Megakaryocyte suspensions that produced microparticles retained their ability to generate proplatelets. These results demonstrate that platelet microparticles are generated from megakaryocytes by an active process that is distinct from platelet formation.
Circulating microparticles manifest features of megakaryocyte-derived microparticles
To test whether or not circulating microparticles are derived from megakaryocytes, we identified surface markers to help distinguish megakaryocyte-derived microparticles from microparticles generated by activated platelets. Three sets of mouse microparticles were analyzed for surface expression of the platelet activation markers CD62P
and LAMP-1. Microparticles generated from activated platelets exposed to thrombin plus collagen demonstrated a 3.5-fold increase in anti-CD62P antibody binding (P = 0.02) and a 3.4-fold increase in anti-LAMP-1 antibody (P = 0.003) binding compared with non-immune IgG (Fig. 5A ). In contrast, megakaryocyte-derived microparticles isolated from cultured fetal megakaryocytes did not express CD62P or LAMP-1 on their surface. Similarly, neither CD62P nor LAMP-1 was identified on circulating mouse microparticles isolated from the plasma of untreated, wild-type mice. These studies demonstrate that neither megakaryocytederived microparticles nor microparticles isolated from the circulation express platelet activation markers.
Results using activation markers are consistent with the supposition that a population of circulating microparticles is derived from megakaryocytes. However, surface markers could potentially be shed in the circulation 41 or during megakaryopoiesis and still be found in the circulation. Thus, we evaluated megakaryocyte-derived microparticles and microparticles isolated from plasma for cleavage of a cytoplasmic protein, filamin A.
Filamin A is a 280 kD actin crosslinking protein that is cleaved by calpain following platelet activation. 21, 42 As expected, resting mouse platelets contained full-length filamin A while activated platelets expressed mostly cleaved filamin A (Fig. 5B) . In contrast, mouse megakaryocytes contained both full-length and cleaved filamin A. Megakaryocyte-derived microparticles demonstrated a ratio of full-length to cleaved filamin A similar to that of megakaryocytes (Fig. 5B) . Filamin A in microparticles generated from activated platelets was almost entirely cleaved. Circulating microparticles isolated from plasma demonstrated a ratio of full-length cleaved filamin A similar to that of microparticles from megakaryocytes.
Together with the surface marker results, these data indicate that CD41 + microparticles circulating in the plasma of healthy wild-type mice share several markers with megakaryocyte-derived microparticles that they do not share with microparticles generated from activated platelets.
Generation of microparticles from human megakaryocytes
To assess the derivation of circulating platelet microparticles in humans, we isolated microparticles from the plasma of healthy volunteers. These samples were assessed for co-expression of the platelet specific antigens CD41 and CD62P. This evaluation demonstrated that only a small portion of CD41 + microparticles express CD62P on their surface (Fig. 6A) . In contrast, the majority of CD41 + microparticles derived from platelets exposed to either collagen plus thrombin or calcium ionophore A23187 express CD62P (Fig.   6A ). These results raise the possibility that platelet microparticles are not derived from activated platelets. Consistent with these findings, we observed that resting platelets isolated from the plasma of healthy individuals contained full-length filamin A (Fig. 6B) . In contrast, activated platelets showed primarily cleaved filamin A. Microparticles derived from plasma contained both full-length and cleaved filamin A, while microparticles derived from activated platelets contained only cleaved filamin A. To assess whether microparticles are generated
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From by unactivated platelets over extended incubations, we incubated platelet-rich plasma with lepirudin to maintain platelets in a resting state. Lack of P-selectin surface expression over a 72 hour period confirmed that platelets were not activated (Supplemental Figure S1A) . Consistent with this observation, filamin A remained uncleaved in platelets incubated under these conditions (Supplemental Figure S1B) . Under conditions in which no platelet activation occurred, no platelet microparticle formation was observed over a 72 hour period (Supplemental Figure S1C) . These data are inconsistent with the premise that platelet microparticles circulating in healthy individuals arise primarily from resting or activated platelets, supporting the possibility that such microparticles derive from an additional or alternative source, such as megakaryocytes.
To directly test whether human megakaryocytes can generate microparticles, we cultured megakaryocytes from human cord blood CD34 + cells and analyzed the supernatants for microparticles. As observed with mouse megakaryocytes, electron microscopy of cultured mouse megakaryocytes revealed a population of cells with particles of 0.2-0.5 μM emanating from the megakaryocyte surface (Fig. 7A ). FACS analysis of CD41 + microparticles from cultured, human megakaryocytes demonstrates that the majority of CD41 + particles also stain with annexin V and anti-CD42b antibody (Fig. 7B) . These results confirm that human megakaryocytes produce microparticles.
Discussion
There is substantial evidence that platelet-derived microparticles (PMPs) are generated in response to pathologic processes including immunologic platelet disorders and arterial thrombosis. [7] [8] [9] [10] PMPs from activated platelets are heterogeneous, 43 but a high 46 The mechanism of their generation, however, and whether such microparticles circulate in plasma was not assessed. We have now characterized microparticles generated by megakaryocytes, demonstrated that the mechanism of their formation is distinct from that of platelets, and have shown that microparticles produced via megakaryocytes manifest features of circulating CD41 + microparticles.
Most studies evaluating circulating platelet microparticles have identified them based on their submicron size, surface expression of CD41 or CD42b, and their ability to bind FITC-annexin V. Megakaryocyte-derived microparticles share these characteristics.
FITC-annexin V binding indicates that despite the fact they arise from a cell that is not activated, megakaryocytic microparticles express PS on their surface. This observation may be related to the phenomenon of localized PS exposure observed in cultured megakaryocytes. 49 The finding that megakaryocyte-derived microparticles are CD62P -, LAMP-1 -, and contain full-length filamin A permits distinction between microparticles formed from activated platelets and those generated directly from megakaryocytes. These We used video-enhanced light microscopy of cultured, living megakaryocytes to demonstrate the generation of microparticles directly from the parent cell of platelets.
Megakaryocytes produce microparticles by a mechanism that is distinct from platelet production. Platelets form at the ends of long tube-like processes called proplatelets that are extended by microtubule-based forces hundreds of micrometers from the megakaryocyte cell body. DIC video microscopy revealed that megakaryocyte-derived microparticles form as beads along the length of slender, unbranched micropodia. High resolution RTM video microscopy showed that microparticles also form from continuous blebbing of the megakaryocyte surface. Microparticle formation generally occurred prior to proplatelet formation; thus, proplatelet extensions were not visualized in videos of microparticleproducing megakaryocytes. To demonstrate conclusively that microparticles were not derived from proplatelets, we inhibited platelet production with the microtubule inhibitor nocodazole. Concentrations of nocodazole (1-5 μM) that inhibit proplatelet formation 50 failed to affect generation of megakaryocyte-derived microparticles (Fig. 4) . Inhibitors of actin polymerization block bending and branching of proplatelet extensions. 31 In contrast, the actin assembly inhibitor latrunculin A augments microparticle formation by megakaryocytes.
These observations indicate that these microparticles are not formed from proplatelets or mature platelets produced during megakaryopoiesis. Video microscopy confirms the For personal use only. on October 3, 2017. by guest www.bloodjournal.org From supposition that platelet microparticles are generated directly from megakaryocytes rather than a platelet intermediate.
Previous studies in mice, rabbits, and dogs have suggested that platelet microparticles are cleared within minutes following introduction into the circulation. [51] [52] [53] The observation that platelet microparticles are cleared rapidly has lead to the proposal that they are produced continuously. Formal possibilities for continuous generation of PMPs include production by resting platelets, production by activated platelets, or production by megakaryocytes. We have not been able to detect platelet microparticle formation over a 72 hour period when resting platelets are incubated in the presence of lepirudin (Supplemental Figure S1 ). Similarly, we have never observed microparticle formation during real time imaging of live resting platelets nor in evaluation of electron micrographs of resting platelets (data not shown). Thus, we have found no evidence that resting platelets generate PMPs.
PMP production by continuous activation of platelets would require continuous activation of platelets to a degree sufficient to result in microparticle formation. One would expect that the degree of platelet activation required to generate this amount of microparticle formation would result in expression of platelet activation markers in circulating platelets, particularly since activated platelets are not necessarily rapidly cleared from the circulation. 41 Surface markers such as P-selectin could be shed from activated platelets. 41 However, filamin A would be cleaved in microparticles generated from platelet activation. An alternative explanation for the maintenance of basal levels of CD41 + microparticles despite rapid clearance is that a population of microparticles is generated directly by megakaryocytes. The observations that circulating microparticles from healthy individuals are CD62P -and contain full-length filamin A support this possibility.
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Based on our observations, we propose that circulating CD41 + microparticles can be derived from two sources. One source is a regulated mechanism in which microparticles are generated directly from mature platelets by activation. Evidence that platelet microparticles can originate from activated platelets in vivo is derived from studies demonstrating increased platelet microparticle levels in patients with thrombotic conditions. [7] [8] [9] 11 The second mechanism of CD41 + microparticle formation is a constitutive mechanism in which microparticles are produced by megakaryocytes. This population is more accurately defined as megakaryocyte-derived microparticles, rather than platelet microparticles, since they arise directly from megakaryocytes and not platelets. The presence of megakaryocyte- Megakaryocyte-derived microparticles and microparticles generated from activated platelets
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From may differ in their mRNA content and, potentially, their ability to influence endothelial cell function. The two microparticle types differ in their expression of platelet activation markers such as P-selectin. Megakaryocyte-derived microparticles may be less capable of supporting inflammatory responses and complement activation compared to those derived from activated platelets. 55, 56 The ability to distinguish PMP from megakaryocyte-derived microparticles could be useful in evaluating the effects of disease states on microparticle levels and for monitoring platelet microparticles for diagnostic and prognostic purposes.
Future comparisons of the two microparticle populations will assess these possibilities.
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